Barton Investment Management Cuts Stake in Johnson & Johnson (NYSE:JNJ)


Share on StockTwits

Barton Investment Management lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,611 shares of the company’s stock after selling 165 shares during the period. Johnson & Johnson comprises approximately 0.3% of Barton Investment Management’s holdings, making the stock its 18th largest holding. Barton Investment Management’s holdings in Johnson & Johnson were worth $3,086,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in JNJ. Principal Financial Group Inc. increased its stake in shares of Johnson & Johnson by 3.6% during the second quarter. Principal Financial Group Inc. now owns 4,445,049 shares of the company’s stock valued at $625,108,000 after buying an additional 152,640 shares during the period. Orion Portfolio Solutions LLC increased its stake in shares of Johnson & Johnson by 11.8% during the second quarter. Orion Portfolio Solutions LLC now owns 16,690 shares of the company’s stock valued at $2,347,000 after buying an additional 1,761 shares during the period. RMR Wealth Builders purchased a new position in shares of Johnson & Johnson during the second quarter valued at $113,000. Asset Dedication LLC grew its stake in Johnson & Johnson by 4.1% in the second quarter. Asset Dedication LLC now owns 13,837 shares of the company’s stock valued at $1,944,000 after purchasing an additional 545 shares during the last quarter. Finally, Fiduciary Planning LLC grew its stake in Johnson & Johnson by 4.0% in the second quarter. Fiduciary Planning LLC now owns 11,845 shares of the company’s stock valued at $1,727,000 after purchasing an additional 457 shares during the last quarter. Hedge funds and other institutional investors own 61.26% of the company’s stock.

Several equities analysts have issued reports on JNJ shares. Raymond James reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Friday, November 20th. Cantor Fitzgerald lifted their target price on Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. Morgan Stanley lifted their target price on Johnson & Johnson from $170.00 to $178.00 and gave the company an “overweight” rating in a research note on Tuesday, December 15th. BidaskClub upgraded Johnson & Johnson from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 6th. Finally, Credit Suisse Group lifted their target price on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research note on Wednesday, October 14th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the stock. Johnson & Johnson has an average rating of “Buy” and a consensus price target of $165.50.

In related news, COO Michael E. Sneed sold 54,662 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, December 9th. The stock was sold at an average price of $152.93, for a total transaction of $8,359,459.66. Following the completion of the transaction, the chief operating officer now directly owns 110,741 shares in the company, valued at $16,935,621.13. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.27% of the stock is currently owned by company insiders.

NYSE JNJ traded down $0.43 during trading on Wednesday, hitting $157.70. The company’s stock had a trading volume of 134,114 shares, compared to its average volume of 8,505,344. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.48 and a quick ratio of 1.24. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $161.32. The company has a market cap of $415.15 billion, a PE ratio of 24.86, a P/E/G ratio of 3.30 and a beta of 0.68. The business’s 50 day simple moving average is $152.58 and its 200-day simple moving average is $148.21.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Sunday, October 18th. The company reported $2.20 EPS for the quarter, topping the Zacks’ consensus estimate of $1.98 by $0.22. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The firm had revenue of $21.08 billion during the quarter, compared to the consensus estimate of $20.15 billion. During the same quarter in the previous year, the company posted $2.12 earnings per share. The company’s revenue was up 1.7% compared to the same quarter last year. Analysts expect that Johnson & Johnson will post 7.99 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 9th. Investors of record on Tuesday, February 23rd will be issued a dividend of $1.01 per share. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.56%. The ex-dividend date is Monday, February 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is 46.54%.

Johnson & Johnson Company Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Article: CBOE Russell 2000® Volatility Index

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.